Arcturus Therapeutics (ARCT) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Arcturus Therapeutics (ARCT) has outperformed Rocket Pharmaceuticals (RCKT) over the past year, gaining 19.0% versus a loss of 33.4%. Over five years, ARCT leads with a -81.3% price change compared with -91.8% for RCKT. Rocket Pharmaceuticals is the larger company by market cap ($217.7 million vs $214.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARCT | RCKT |
|---|---|---|
| Share price | $7.45 | $1.95 |
| Market cap | $214.73M | $217.74M |
| 1-day change | -1.97% | -7.58% |
| YTD return | +21.53% | -44.44% |
| 1-year return | +19.01% | -33.45% |
| 5-year return | -81.32% | -91.76% |
| EPS (TTM) | $-3.10 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $82.03M | $0 |
| Revenue growth (YoY) | -46.14% | — |
| Net income (latest FY) | $-65.78M | $-223.12M |
| Operating margin | -92.96% | — |
| Net margin | -80.19% | — |
| 52-week high | $17.96 | $5.45 |
| 52-week low | $5.50 | $1.94 |
| Distance from 52-week high | -58.52% | -64.22% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +218.12% | +326.15% |
| Average volume | 851.45K | 1.90M |
| Shares outstanding | 28.82M | 111.66M |
| Employees | 106 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARCT has outperformed RCKT by 52.5 percentage points over the past year.
About Arcturus Therapeutics
ARCT stock →Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
ARCT vs RCKT FAQ
Which is bigger, Arcturus Therapeutics or Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) is larger, with a market capitalization of $217.74M compared with $214.73M for Arcturus Therapeutics (ARCT).
Which stock has performed better over the past year, ARCT or RCKT?
ARCT returned +19.01% over the past 12 months, compared with -33.45% for RCKT (price return, excluding dividends). Past performance does not predict future results.
Are Arcturus Therapeutics and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.